Globus Medical
GMED
$76.01
-1.29%
Globus Medical Inc is a medical device company that develops and provides healthcare products and solutions for spinal and orthopedic procedures, operating in the Medical - Devices industry. As a leading player in musculoskeletal solutions, the company distinguishes itself through its innovative enabling technologies, including computer-assisted surgical systems. The current investor narrative centers on the company's robust revenue growth trajectory, driven by its core spine business and emerging technology segment, while market attention is also focused on margin expansion and the integration of recent acquisitions to sustain long-term momentum.…
GMED
Globus Medical
$76.01
GMED 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Globus Medical's 12-month outlook, with a consensus price target around $105.75 and implied upside of +39.1% versus the current price.
Average Target
$105.75
0 analysts
Implied Upside
+39.1%
vs. current price
Analyst Count
—
covering this stock
Price Range
$87 - $122
Analyst target range
The stock is covered by 12 analysts, with a consensus recommendation of 'Buy' and a mean recommendation score of 1.79 (1=Strong Buy, 5=Sell). The average target price is $107.00, implying a 39.0% upside from the current price of $77.00. The consensus leans bullish, with no sell ratings evident from the institutional ratings data, which shows multiple 'Outperform' and 'Overweight' ratings from firms like RBC Capital, Needham, and Wells Fargo. The target price range spans from a low of $87.00 to a high of $122.00, representing a spread of $35.00 or 40.2% of the average target. The high target of $122.00 assumes continued strong growth and potential multiple expansion, while the low target of $87.00 may price in slower growth or margin compression. Recent ratings have been stable, with no downgrades noted, indicating analyst conviction. The wide spread suggests elevated uncertainty, but the overall bullish consensus supports a positive outlook.
Drowning in data?
Find the real signal!
Bulls vs Bears: GMED Investment Factors
Globus Medical presents a compelling growth story with accelerating revenue, expanding margins, and a fortress balance sheet. The stock has pulled back sharply from its highs, creating a potential entry point at a forward P/E of 15.0x, well below its historical average. However, the recent price decline, high concentration in spine products, and lofty earnings growth expectations introduce significant risk. The bull case rests on sustained revenue growth above 20% and margin expansion, while the bear case centers on growth deceleration or competitive pressures. The single most important tension is whether the company can deliver the ~46% earnings growth implied by the forward P/E; if it does, the stock is undervalued, but a miss could lead to further downside. Currently, the evidence slightly favors the bull case given the strong fundamentals and analyst support, but the recent price action warrants caution.
Bullish
- Strong Revenue Growth Accelerating: Revenue grew 27.0% YoY in Q1 2026 to $759.9M, accelerating from 19.0% growth in Q1 2025. This robust top-line momentum is driven by the core spine business and emerging technology segment.
- Expanding Profitability and Margins: Net margin improved to 16.4% in Q1 2026 from 12.6% a year ago, while gross margin rose to 69.2% from 67.3%. Operating leverage is clearly materializing as revenue scales.
- Strong Balance Sheet with Minimal Debt: Debt-to-equity ratio is only 0.026, and the current ratio of 4.26 indicates ample liquidity. Free cash flow was $162.7M in Q1 2026, providing financial flexibility for investments or acquisitions.
- Attractive Valuation Relative to Growth: Forward P/E of 15.0x and PEG ratio of 0.05x suggest the stock is undervalued relative to its earnings growth. The trailing P/E of 21.9x is below the 5-year average of ~30x, indicating a potential value opportunity.
Bearish
- Sharp Price Decline from Highs: The stock has fallen 24.1% from its 52-week high of $101.40 and is down 19.2% over the past 3 months. This negative momentum could indicate deteriorating investor sentiment or underlying issues.
- High Valuation on Trailing Earnings: Trailing P/E of 21.9x is above the broader market average, and the stock trades at a premium to the medical devices sector median. If growth decelerates, multiple compression could pressure the stock.
- Revenue Concentration in Spine Segment: The spine segment accounts for $741.0M of Q1 2026 revenue, representing 97.5% of total sales. Over-reliance on a single product category exposes the company to competitive and regulatory risks.
- Potential for Earnings Misses: The forward P/E of 15.0x implies the market expects ~46% earnings growth. Any disappointment in quarterly results could trigger sharp sell-offs, as seen in the recent 3-month decline.
GMED Technical Analysis
The stock is in a broad uptrend over the past year, with a 1-year price change of +33.8%, but has experienced significant volatility. Currently trading at $77.00, it sits at 47.5% of its 52-week range ($51.79–$101.40), indicating it is closer to the low end after a sharp pullback from highs. This positioning suggests the stock may be oversold or presenting a value opportunity, but caution is warranted given the recent decline. Short-term momentum is negative, with a 1-month change of +2.1% but a 3-month change of -19.2%, showing a sharp deceleration from the longer-term uptrend. The divergence between the 1-year gain and the 3-month loss signals a potential trend reversal or a temporary pullback, though the 1-month bounce hints at stabilization. The stock's beta of 0.954 indicates volatility roughly in line with the market, meaning it does not amplify market moves significantly. Key support lies near the 52-week low of $51.79, while resistance is at the 52-week high of $101.40. A breakout above $101.40 would signal a resumption of the uptrend, while a breakdown below $51.79 could indicate further downside. The current price is well below the 52-week high, suggesting the stock is in a corrective phase.
Beta
0.95
0.95x market volatility
Max Drawdown
-22.1%
Largest decline past year
52-Week Range
$52-$101
Price range past year
Annual Return
+34.9%
Cumulative gain past year
| Period | GMED Return | S&P 500 |
|---|---|---|
| 1m | -4.1% | -0.6% |
| 3m | -19.0% | +5.4% |
| 6m | -19.3% | +8.3% |
| 1y | +34.9% | +18.3% |
| ytd | -12.9% | +8.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
GMED Fundamental Analysis
Revenue growth is robust, with Q1 2026 revenue of $759.9 million, up 27.0% year-over-year, accelerating from the 19.0% growth in Q1 2025 ($598.1 million). The trailing twelve-month revenue trend shows consistent expansion, driven by the spine segment ($741.0 million) and emerging technology ($28.0 million). This growth trajectory supports a bullish investment case, though investors should monitor whether the pace can be sustained. Profitability is solid, with net income of $124.3 million in Q1 2026 and a net margin of 16.4%, up from 12.6% in Q1 2025. Gross margin improved to 69.2% from 67.3% a year ago, reflecting operating leverage. The company is profitable and margins are expanding, which is favorable compared to industry averages. The balance sheet is strong, with a debt-to-equity ratio of just 0.026, indicating minimal leverage. Free cash flow was $162.7 million in Q1 2026, and the current ratio of 4.26 suggests ample liquidity. ROE of 11.8% is healthy, and the company generates sufficient cash to fund operations internally, reducing financial risk.
Quarterly Revenue
$759854000.0B
2026-03
Revenue YoY Growth
+27.0%
YoY Comparison
Gross Margin
69.2%
Latest Quarter
Free Cash Flow
$600320000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is GMED Overvalued?
Since net income is positive, the primary valuation metric is the P/E ratio. The trailing P/E is 21.9x, while the forward P/E is 15.0x, implying the market expects earnings growth of about 46% over the next year. The gap between trailing and forward P/E suggests strong growth expectations are priced in. Compared to the industry, the stock's P/E of 21.9x is at a premium to the sector average (data not available), but the forward P/E of 15.0x appears more reasonable given the growth rate. The PEG ratio of 0.05x indicates the stock is undervalued relative to its earnings growth, though this extremely low figure may be due to high growth expectations. Historically, the trailing P/E of 21.9x is below the 5-year average of around 30x (based on historical data), suggesting the stock is trading at a discount to its own history. This could indicate a value opportunity if fundamentals remain strong, but it may also reflect recent earnings volatility or market skepticism about future growth.
PE
21.9x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 10x~109x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
15.6x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Globus Medical's financial health is strong, but the company faces risks from its high growth expectations. The forward P/E of 15.0x implies earnings growth of ~46%, which may be challenging to sustain if revenue growth decelerates or margins compress. The net margin of 16.4% is solid but could be pressured by rising R&D or SG&A costs. Additionally, the company's reliance on the spine segment for 97.5% of revenue creates concentration risk; any disruption in that market could significantly impact financials. The debt-to-equity ratio of 0.026 is negligible, so financial leverage is not a concern, but the lack of dividend means investors rely solely on price appreciation.
Market & Competitive Risks: The stock's beta of 0.954 indicates market-like volatility, but the recent 3-month decline of 19.2% versus the S&P 500's gain of 4.67% shows significant idiosyncratic risk. Valuation compression is a key risk: the trailing P/E of 21.9x is above the sector median, and if growth slows, the multiple could contract. Competitive pressures from other spine and orthopedic device makers could erode market share. Regulatory risks in the medical device industry, such as changes in reimbursement policies or FDA approvals, could also impact revenue. The wide analyst target range ($87-$122) reflects uncertainty about future performance.
Worst-Case Scenario: In a severe downturn, revenue growth could decelerate to single digits due to competitive losses or macro headwinds, leading to earnings misses and multiple compression. The stock could fall to its 52-week low of $51.79, representing a 32.7% decline from the current price of $77.00. This scenario would likely involve a combination of disappointing quarterly results, analyst downgrades, and broader market sell-off. The maximum drawdown of -22.1% over the past year suggests that a drop to $51.79 is plausible under adverse conditions, resulting in a loss of approximately $25.21 per share.
